



28 May 2018

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Further to the Appendix 3B lodged on 28 May 2018 for the issue of 187,122,994 fully paid ordinary shares (**Placement**), Actinogen Medical Limited (ASX: ACW) provides the following information required under ASX Listing Rule 3.10.5A:

(a) The dilutive effect of the Placement on existing shareholders is as follows:

Number of Shares on issue prior to the Placement: 753,193,558

Placement issue under Listing Rule 7.1 (111,803,639 shares)	14.84%
Placement issue under Listing Rule 7.1A (75,319,355 shares)	10.00%
Total dilution as a result of the Placement	24.84%

Number of Shares on issue following the Placement: 940,316,552

Details of the approximate percentage of the issued capital following the completion of the Placement held by pre-Placement shareholders and new shareholders are as follows. Please note this information relates specifically in relation to the portion of shares issued under Listing Rule 7.1A (75,319,355 shares):

Pre-Placement shareholders who did not participate in the Placement	100%
Pre-Placement shareholders who did participate in the Placement	-
Participants in the Placement who were previously not shareholders	100%

- (b) The Company issued the shares as a placement under Listing Rule 7.1A as it believed that this was the most efficient mechanism for raising funds at the time as it gives the Company certainty of raising the amount of capital and also gives the Company exposure to US and other institutional investors.
- (c) No underwriting arrangements were in place for the Placement; and
- (d) The commission for the Placement is 5% of the total funds raised.

Yours faithfully

A handwritten signature in dark ink, appearing to read "Peter Webse".

Peter Webse
Company Secretary